|Home | About | Journals | Submit | Contact Us | Français|
Prompt diagnosis and management of community acquired pneumonia saves lives. This article summarises the latest key recommendations in the management of pneumonia and is intended for junior doctors managing this common condition
Community acquired pneumonia is an important healthcare concern. The annual incidence rate is 6/1000 in the 18-39 age group. This rises to 34/1000 in people aged 75 years and over. Admission to hospital is needed in 20-40% of patients with community acquired pneumonia. About 5-10% of these patients are admitted to intensive care. The overall mortality from community acquired pneumonia is 5-10%, so it is important to identify and treat patients with this disease.1,2 We will concentrate on three aspects of hospital management: assessment of disease severity, investigations, and antibiotic treatment.
Pneumonia is defined as an acute lower respiratory tract infection, together with new radiographic shadowing.1 Anybody can get pneumonia, although it is most common in elderly people. The clinical history of pneumonia may include one or more of:
On examination the signs may include:
In elderly people, fever may not be present and new onset of mental confusion is more common.3
Pneumonia is common and has high mortality
Simple scoring systems help to distinguish between patients who can be managed at home and those who may need intensive care
Antibiotic treatment is guided by the severity of disease
Newer antibiotics have their place, but penicillin and macrolides (such as erythromycin) are still first line drugs
Table 1 lists the other diagnoses that should be considered when patients present with focal chest signs and increasing shortness of breath. A chest x ray is crucial to making the diagnosis of pneumonia. New chest signs on examination are helpful but not specific. One clinical study conducted in primary care in the United Kingdom showed that only 40% of patients with new lower respiratory tract symptoms and focal chest signs had radiological evidence of pneumonia.4
About 40% of patients have a pleural effusion, but the amount of fluid is usually small.1 A microbiological diagnosis can be made on routine microbiological tests in only about 15% of inpatients; this percentage is even lower in patients with mild or moderate pneumonia and no comorbid illnesses.5 The following tests are recommended for patients admitted with non-severe community acquired pneumonia:
In patients with severe pneumonia, tests for atypical pathogens (Mycoplasma pneumoniae, Chlamydia sp, Coxiella burnetii, Legionella sp) and viruses should also be carried out. These are:
Testing for pneumococcal urinary antigen is also recommended in severe pneumonia.
Severe pneumonia has a high mortality, so it is important to identify patients at high risk of complications and death. Many studies have looked at features associated with poor prognosis. More than 40 indicators of poor prognosis have been identified, and complex scoring systems have been developed.6 The most widely studied one is a North American 20 point system,7 but this system is not practical in many clinical settings and is not used widely in the UK.
The British Thoracic Society recommends the CURB-65 scoring system.8,9 This is a 6 point score (range 0-5) that gives one point each for confusion (abbreviated mental test score ≤ 8 or new disorientation in person, place, or time); urea > 7 mmol/l; respiratory rate ≥ 30/min; low blood pressure (systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg); and age 65 years or more. The score relates to mortality, and severe pneumonia is defined as a CURB-65 score of 3 or more. The British Thoracic Society advocates management strategies based on this score (fig 1).
Clinical judgment is needed when using the scoring system. If the score is low but the patient is unwell he or she could still have severe pneumonia. For example, a young person with normal blood pressure and urea but low oxygen saturation despite supplemental oxygen could have severe pneumonia and may need to be reviewed by the intensive care team.
Pneumonia must be treated with the appropriate antibiotics. Table 2 shows the current recommendations of the British Thoracic Society for empirical treatment of community acquired pneumonia.pneumonia.
Since the development of new fluoroquinolones with enhanced activity against Gram positive organisms (such as Streptococcus pneumoniae), the choice of antibiotic for respiratory tract infections has broadened. Two such agents currently available in the UK are levofloxacin and moxifloxacin. These antimicrobials are active against atypical pathogens and Streptococcus pneumoniae. However, concerns exist about the widespread use of these drugs as they have been associated with the emergence of fluoroquinolone resistant streptococci, an increase in the development of methicillin resistant Staphylococcus aureus (MRSA), and diarrhoea associated with Clostridium difficile infection.10,11
The new fluoroquinolones are not recommended for use in the community but should be reserved for the hospital setting. Currently in the UK, only levofloxacin has a licensed intravenous preparation. This is expensive and not available in many hospitals.
Patients should receive intravenous antibiotics if they have:
Intravenous antibiotics should be changed to oral as soon as possible. Resolution of the patient's fever, improved oxygen status, and haemodynamic stability are indicators for oral treatment.
In non-severe pneumonia, antibiotics should be given for seven days. Patients with severe pneumonia but no microbiological confirmation usually receive 10 days of intravenous drugs. Patients who are infected with Legionella sp, S aureus, and Gram negative bacteria should receive 14-21 days of antimicrobial treatment.
Measuring C reactive protein (an acute phase protein) concentrations is useful for managing pneumonia. Ninety five percent of patients admitted with community acquired pneumonia have a C reactive protein value > 50 mg/l.12 The initial concentration of this protein does not correlate closely with the severity of disease, but it can be used as an indicator of response to treatment. Treatment failure or complications (such as an empyema) should be considered if C reactive protein is not 50% lower by the fourth day.13
It is important to know when it is safe to discharge patients. Features of clinical instability are:
One study showed that 40% of patients who had two or more of these features within 24 hours before they were discharged died or were readmitted within 30 days, compared with 11% of those with none of these features.14
Every patient with pneumonia should be reviewed about six weeks after discharge. In patients with poor clinical recovery, a chest x ray should be done to identify those with possible underlying malignancy. Patients with a high risk of malignancy, such as those who smoke or who are aged over 50 years, should also have a repeat chest x ray at six weeks.
Competing interests: None declared.
Editorial by Goossens and Little
This article is based on a module that is available on BMJ Learning (www.bmjlearning.com)